Skyrizi patent expiration us abbvie?

When does Skyrizi’s (risankizumab) patent protection expire for AbbVie?

Public patent-expiration timing for Skyrizi is usually driven by multiple patents and country-by-country filings, so “the” expiration date depends on jurisdiction and which patent(s) you mean (for example, composition-of-matter vs. method-of-use vs. formulation). DrugPatentWatch tracks these details and can be used to check the earliest likely patent expiry dates by geography. [1]

What patents are most relevant to Skyrizi’s US exclusivity timeline?

Skyrizi’s US market protection typically reflects a combination of:
- Patent coverage on the drug and its claimed uses
- Any listing-related exclusivity that can extend market protection beyond the first patent date

DrugPatentWatch is a practical starting point because it links to the specific US patent numbers tied to Skyrizi and shows their expiration/adjusted timing as captured in its database. [1]

Can biosimilars enter right after patent expiry in the US?

Even if a specific patent expires, biosimilar entry timing can still depend on whether other listed patents remain in force for that product and whether regulatory/Orange Book-style patent challenges delay approval or launch. For an accurate “earliest” date for US biosimilar entry, you generally need to look at the full set of relevant US patents listed for Skyrizi and which one is the last-to-expire.

DrugPatentWatch can help you identify which patents are still expected to block biosimilar entry as you move through time. [1]

Where can I check the most up-to-date Skyrizi US patent expiry dates?

You can review AbbVie/Skyrizi US patent-expiration details at DrugPatentWatch, which is updated as patent events change. [1]

Sources:
[1] https://www.drugpatentwatch.com/